<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943238</url>
  </required_header>
  <id_info>
    <org_study_id>50540</org_study_id>
    <nct_id>NCT03943238</nct_id>
  </id_info>
  <brief_title>TLI, ATG &amp; Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation</brief_title>
  <official_title>Phase 1 Study of Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+, T-cell and Recipient T Regulatory Cell Transfusion in Human Leukocyte Antigen Mismatched Living Donor Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether a preparatory regimen including total lymphoid irradiation
      (TLI), anti-thymocyte globulin (ATG) and infusion of the donor hematopoietic stem cells when
      given along with recipient regulatory T cells (Tregs) will allow for eventual discontinuation
      of anti-rejection drugs after living donor kidney transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been demonstrated that hematopoietic mixed chimerism or the coexistence of both donor
      and recipient immune cells can lead to tolerance to the graft in absence of graft versus host
      disease (GVHD). The goal of this pilot study is to determine if recipients of living donor
      kidney transplant can be successfully withdraw from immunosuppressive drugs. The patients
      will receive a preparatory regimen consisting of TLI and ATG following their kidney
      transplantation. Two weeks later, they will receive purified hematopoietic stem cells (CD34+)
      and Tcells that have been collected 6 weeks prior from their kidney donor. Regulatory T cells
      (Tregs) that have been collected from the recipient prior to the transplantation and expanded
      in vitro will be infuse the following day to enhance the chance of engraftment of the donor
      bone marrow cells. If chimerism develops and persists, the immunosuppressive drug will be
      tapered and stop. Mycophenolate mofetil (MMF) will be stopped 12 months after transplantation
      and if the chimerism remains stable, tacrolimus will be stopped 6 months later. The dose of
      Tregs will be escalated if the % of donor chimerism is not at least 25% during the first 60
      days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>In this phase 1 study, a conditioning regimen of Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donr CD34+, T cell and Recipient T regulatory Cell Transfusion in Human Leukocyte Antigen Mismatched Living Donor Kidney Transplantation will be studied</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of participants with sustained mixed chimerism of &gt;25% at 18 months</measure>
    <time_frame>Month 18</time_frame>
    <description>Chimerism is defined as the co-existence of the immune cell from both the donor and the recipient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Count of participants able to withdraw from immunosuppressive drugs without evidence of rejection at 18 months</measure>
    <time_frame>Month 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Count of participants with adverse events associated with the infusion of the Tregs cell product</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of participants with bacterial, viral, or fungal infections</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Living Donor Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Combined kidney/stem cell transplants and recipient's Tregs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preparatory regimen including TLI, ATG after kidney transplantation followed by infusion of donor CD34+, T cell and recipient Tregs</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs</intervention_name>
    <description>Living donor kidney transplant recipients will receive after a preparatory regimen of total lymphoid irradiation and and anti-thymocyte globulin an infusion of purified donor CD34+ of &gt;10 x10^6 cells /Kg, 100 x 10^6 donor T cell/ Kg and and an escalated dose of recipient Tregs starting at 25 x10^6/Kg.</description>
    <arm_group_label>Combined kidney/stem cell transplants and recipient's Tregs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All consenting adults who are 18 to 65 years, living donor renal transplant recipients
             at Stanford University Medical Center or Northwestern Medicine who have a haplotype
             matched (minimum single Human Leukocyte Antigen - DR locus (HLA-DR) and HLA-A or B
             match) living related or unrelated donor.

          2. Patients who agree to participate in the study and sign an Informed Consent.

          3. Patients who have no known contraindication to administration of rabbit ATG or
             radiation.

          4. Males and females of reproductive potential who agree to practice a reliable form of
             contraception for at least 1 year posttransplant

        Exclusion Criteria:

          1. Previous treatment with rabbit ATG or a known allergy to rabbit proteins.

          2. History of malignancy with the exception of non-melanoma skin malignancies.

          3. Pregnant women or nursing mothers.

          4. Serological evidence of HIV, Hepatitis B surface antigen positive (HBsAg+), or
             Hepatitis C infection. Epstein Barr Virus (EBV) positive to EBV negative.

          5. Leukopenia (with a white blood cell count &lt; 3000/mm3) or thrombocytopenia (with a
             platelet count &lt; 100,000/mm3).

          6. Panel Reactive Antibody (PRA) greater than 80% or demonstration of historic and/or
             current donor specific antibody (DSA)

          7. Prior organ transplantation

          8. High risk of primary kidney disease recurrence

          9. Advanced coronary or vascular disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Everett Meyer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asha Shori, CCRP</last_name>
    <phone>650-736-0245</phone>
    <email>ashas@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Busque, MD</last_name>
    <phone>650-498-6189</phone>
    <email>sbusque@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asha Shori, CCRP</last_name>
      <phone>650-736-0245</phone>
      <email>ashas@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephan Busque, MD</last_name>
      <phone>650-498-6189</phone>
      <email>sbusque@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Everett Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lowsky Robert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hoppe Richard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scandling John, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Strober Samuel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kent Jensen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Busque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nothwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Stare, RN</last_name>
      <phone>312-694-0240</phone>
      <email>diane.stare@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joseph Leventhal, MD</last_name>
      <phone>312-695-8900</phone>
      <email>jleventh@nm.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jayesh Mehta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Mathew, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenzo Gallon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Leventhal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Leventhal JR, Ildstad ST. Tolerance induction in HLA disparate living donor kidney transplantation by facilitating cell-enriched donor stem cell Infusion: The importance of durable chimerism. Hum Immunol. 2018 May;79(5):272-276. doi: 10.1016/j.humimm.2018.01.007. Epub 2018 Mar 2. Review.</citation>
    <PMID>29409743</PMID>
  </reference>
  <reference>
    <citation>Ildstad ST, Leventhal J, Wen Y, Yolcu E. Facilitating cells: Translation of hematopoietic chimerism to achieve clinical tolerance. Chimerism. 2015 Apr 3;6(1-2):33-9. doi: 10.1080/19381956.2015.1130780. Epub 2016 Jan 8.</citation>
    <PMID>26745761</PMID>
  </reference>
  <reference>
    <citation>Scandling JD, Busque S, Shizuru JA, Lowsky R, Hoppe R, Dejbakhsh-Jones S, Jensen K, Shori A, Strober JA, Lavori P, Turnbull BB, Engleman EG, Strober S. Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation. Am J Transplant. 2015 Mar;15(3):695-704. doi: 10.1111/ajt.13091.</citation>
    <PMID>25693475</PMID>
  </reference>
  <reference>
    <citation>Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney transplantation. N Engl J Med. 2011 Oct 6;365(14):1359-60. doi: 10.1056/NEJMc1107841.</citation>
    <PMID>21991976</PMID>
  </reference>
  <reference>
    <citation>Scandling JD, Busque S, Lowsky R, Shizuru J, Shori A, Engleman E, Jensen K, Strober S. Macrochimerism and clinical transplant tolerance. Hum Immunol. 2018 May;79(5):266-271. doi: 10.1016/j.humimm.2018.01.002. Epub 2018 Jan 9. Review.</citation>
    <PMID>29330112</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>March 22, 2020</last_update_submitted>
  <last_update_submitted_qc>March 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Everett Meyer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>kidney transplant</keyword>
  <keyword>Immunological Tolerance</keyword>
  <keyword>Tregs</keyword>
  <keyword>Stem cells</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

